Evidence map›Paper›PMID 37626693›Full record

ArticleBiomedicines2023

Identification of NOX4 as a New Biomarker in Hepatocellular Carcinoma and Its Effect on Sorafenib Therapy.

Hui-Zhou Li, Qing-Qing Liu, De-Hua Chang, Shu-Xian Li, Long-Tao Yang, Peng Zhou, Jiang-Bei Deng, Chang-Hao Huang, Yu-Dong Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Hui-Zhou LiDepartment of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Qing-Qing LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
De-Hua ChangDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Shu-Xian LiDepartment of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Long-Tao YangDepartment of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Peng ZhouDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Jiang-Bei DengDepartment of Intervention, Changsha Central Hospital, University of South Chian, Changsha 410011, China.
Chang-Hao HuangThe Hunan Provincial Key Laboratory of Precision Diagnosis and Treatment for Gastrointestinal Tumor, Xiangya Hospital, Central South University, Changsha 410008, China.
Yu-Dong XiaoDepartment of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.ORCID 0000-0002-6815-3447
Central South University · CNChangsha Central Hospital · CNHeidelberg University · DE

Funding

Natural Science Foundation of Hunan Province 2021JJ30964Postgraduate Independent Exploration and Innovation Project of Central South University of China 2019zzts096
6 · The paper itself

Abstract

To improve the survival of patients with hepatocellular carcinoma (HCC), new biomarkers and therapeutic targets are urgently needed. In this study, the GEO and TCGA dataset were used to explore the differential co-expressed genes and their prognostic correlation between HCC and normal samples. The mRNA levels of these genes were validated by qRT-PCR in 20 paired fresh HCC samples. The results demonstrated that the eight-gene model was effective in predicting the prognosis of HCC patients in the validation cohorts. Based on qRT-PCR results, NOX4 was selected to further explore biological functions within the model and 150 cases of paraffin-embedded HCC tissues were scored for NOX4 immunohistochemical staining. We found that the NOX4 expression was significantly upregulated in HCC and was associated with poor survival. In terms of function, the knockdown of NOX4 markedly inhibited the progression of HCC in vivo and in vitro. Mechanistic studies suggested that NOX4 promotes HCC progression through the activation of the epithelial-mesenchymal transition. In addition, the sensitivity of HCC cells to sorafenib treatment was obviously decreased after NOX4 overexpression. Taken together, this study reveals NOX4 as a potential therapeutic target for HCC and a biomarker for predicting the sorafenib treatment response.

Indexed as

epithelial–mesenchymal transitionhepatocellular carcinomaNOX4sorafenib resistance

Identifiers

PMID37626693
PMCPMC10452076
OpenAlexW4385576453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.